Guggenheim Maintains Buy on Sionna Therapeutics, Raises Price Target to $60

Benzinga · 2d ago
Guggenheim analyst Yatin Suneja maintains Sionna Therapeutics (NASDAQ:SION) with a Buy and raises the price target from $50 to $60.